Hajduk PJ - Search Results

1

Druggability indices for protein targets derived from NMR-based screening data.

Hajduk PJ, Huth JR, Fesik SW. Hajduk PJ, et al. J Med Chem. 2005 Apr 7;48(7):2518-25. doi: 10.1021/jm049131r. J Med Chem. 2005. PMID: 15801841

2

Structure of the N-terminal RNA-binding domain of the SARS CoV nucleocapsid protein.

Huang Q, Yu L, Petros AM, Gunasekera A, Liu Z, Xu N, Hajduk P, Mack J, Fesik SW, Olejniczak ET. Huang Q, et al. Biochemistry. 2004 May 25;43(20):6059-63. doi: 10.1021/bi036155b. Biochemistry. 2004. PMID: 15147189

3

A strategy for high-throughput assay development using leads derived from nuclear magnetic resonance-based screening.

Hajduk PJ, Betz SF, Mack J, Ruan X, Towne DL, Lerner CG, Beutel BA, Fesik SW. Hajduk PJ, et al. J Biomol Screen. 2002 Oct;7(5):429-32. doi: 10.1177/108705702237674. J Biomol Screen. 2002. PMID: 14599358

4

NMR-driven discovery of benzoylanthranilic acid inhibitors of far upstream element binding protein binding to the human oncogene c-myc promoter.

Huth JR, Yu L, Collins I, Mack J, Mendoza R, Isaac B, Braddock DT, Muchmore SW, Comess KM, Fesik SW, Clore GM, Levens D, Hajduk PJ. Huth JR, et al. Among authors: hajduk pj. J Med Chem. 2004 Sep 23;47(20):4851-7. doi: 10.1021/jm0497803. J Med Chem. 2004. PMID: 15369388

5

Utilization of NMR-derived fragment leads in drug design.

Huth JR, Sun C, Sauer DR, Hajduk PJ. Huth JR, et al. Among authors: hajduk pj. Methods Enzymol. 2005;394:549-71. doi: 10.1016/S0076-6879(05)94023-8. Methods Enzymol. 2005. PMID: 15808237

6

Predicting protein druggability.

Hajduk PJ, Huth JR, Tse C. Hajduk PJ, et al. Drug Discov Today. 2005 Dec;10(23-24):1675-82. doi: 10.1016/S1359-6446(05)03624-X. Drug Discov Today. 2005. PMID: 16376828 Review.

7

Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis.

Petros AM, Dinges J, Augeri DJ, Baumeister SA, Betebenner DA, Bures MG, Elmore SW, Hajduk PJ, Joseph MK, Landis SK, Nettesheim DG, Rosenberg SH, Shen W, Thomas S, Wang X, Zanze I, Zhang H, Fesik SW. Petros AM, et al. Among authors: hajduk pj. J Med Chem. 2006 Jan 26;49(2):656-63. doi: 10.1021/jm0507532. J Med Chem. 2006. PMID: 16420051

8

Scaffold oriented synthesis. Part 2: Design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitors.

Gracias V, Ji Z, Akritopoulou-Zanze I, Abad-Zapatero C, Huth JR, Song D, Hajduk PJ, Johnson EF, Glaser KB, Marcotte PA, Pease L, Soni NB, Stewart KD, Davidsen SK, Michaelides MR, Djuric SW. Gracias V, et al. Among authors: hajduk pj. Bioorg Med Chem Lett. 2008 Apr 15;18(8):2691-5. doi: 10.1016/j.bmcl.2008.03.021. Epub 2008 Mar 10. Bioorg Med Chem Lett. 2008. PMID: 18362070

9

Discovery of a potent and selective Bcl-2 inhibitor using SAR by NMR.

Petros AM, Huth JR, Oost T, Park CM, Ding H, Wang X, Zhang H, Nimmer P, Mendoza R, Sun C, Mack J, Walter K, Dorwin S, Gramling E, Ladror U, Rosenberg SH, Elmore SW, Fesik SW, Hajduk PJ. Petros AM, et al. Among authors: hajduk pj. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6587-91. doi: 10.1016/j.bmcl.2010.09.033. Epub 2010 Sep 15. Bioorg Med Chem Lett. 2010. PMID: 20870405

10

NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailability.

Hajduk PJ, Shuker SB, Nettesheim DG, Craig R, Augeri DJ, Betebenner D, Albert DH, Guo Y, Meadows RP, Xu L, Michaelides M, Davidsen SK, Fesik SW. Hajduk PJ, et al. J Med Chem. 2002 Dec 19;45(26):5628-39. doi: 10.1021/jm020160g. J Med Chem. 2002. PMID: 12477346

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

89 results

Search Page